Bicoll specializes in the discovery and development of novel small molecules derived from plant-based natural compounds, focusing on applications in the pharmaceutical, nutraceutical, and agricultural sectors. Their proprietary technologies, such as BILOBAC N™, BIFRAC N™, and BIPRESELECT™, facilitate the creation of extensive natural compound libraries that are essential for drug discovery. These libraries are designed to be user-friendly and cost-effective, allowing for efficient screening and identification of active agents. Bicoll's approach emphasizes the importance of natural compounds, which have been shown to be highly relevant in drug development, with a significant percentage of top-selling pharmaceuticals being engineered from natural sources.

The company is particularly focused on addressing neurodegenerative disorders and promoting longevity through the development of preclinical candidates. Bicoll's partnerships with academic institutions and industry leaders enhance their research capabilities, enabling them to explore innovative solutions for health-related challenges. Their collaborative projects, such as the SimLeap consortium, aim to leverage historical knowledge of plant-based remedies to create healthier food formulations. Bicoll's commitment to scientific excellence and innovation is further demonstrated by their numerous peer-reviewed publications and patents, solidifying their position as a trusted partner in the field of medicinal chemistry and natural product research.

Germany

Bicoll is an expert in bioactive plant-derived small molecules with outstanding expertise in high-tech natural product chemistry and validated experience in medicinal chemistry.
Currently Bicoll focuses on two main fields such as neurodegenerative disorders (primarily, epilepsy) and longevity. In both of the fields it develops own preclinical candidates.

Bicoll

Company Details